PROTAGONIST THERAPEUTICS INC's ticker is PTGX and the CUSIP is 74366E102. A total of 67 filers reported holding PROTAGONIST THERAPEUTICS INC in Q4 2018. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $2,300,746 | +15.8% | 83,300 | -3.6% | 0.05% | +25.0% |
| Q1 2023 | $1,987,200 | +333.9% | 86,400 | +49.2% | 0.04% | +233.3% |
| Q2 2022 | $458,000 | -88.8% | 57,923 | -66.5% | 0.01% | -87.4% |
| Q1 2022 | $4,095,000 | +808.0% | 172,941 | +1210.2% | 0.10% | +763.6% |
| Q4 2021 | $451,000 | +176.7% | 13,200 | -42.7% | 0.01% | -21.4% |
| Q1 2020 | $163,000 | +79.1% | 23,039 | +78.7% | 0.01% | +75.0% |
| Q4 2019 | $91,000 | -84.5% | 12,893 | -73.7% | 0.01% | -85.2% |
| Q3 2019 | $588,000 | -54.2% | 48,972 | -53.8% | 0.05% | -53.8% |
| Q2 2019 | $1,283,000 | +857.5% | 105,965 | +432.0% | 0.12% | +485.0% |
| Q4 2018 | $134,000 | – | 19,917 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| JOHNSON & JOHNSON | 2,449,183 | $43,400,000 | 3.81% |
| BVF INC/IL | 3,901,759 | $69,139,000 | 2.70% |
| COMMODORE CAPITAL LP | 498,079 | $8,826,000 | 2.33% |
| Altium Capital Management LP | 346,000 | $6,131,000 | 1.61% |
| Twin Lakes Capital Management, LLC | 139,287 | $2,468,000 | 1.45% |
| Opaleye Management Inc. | 330,222 | $5,852,000 | 1.09% |
| EcoR1 Capital, LLC | 1,443,800 | $25,584,000 | 0.89% |
| OBERMEYER WOOD INVESTMENT COUNSEL, LLLP | 776,689 | $13,763,000 | 0.76% |
| JABODON PT CO | 90,656 | $1,606,000 | 0.66% |
| Artal Group S.A. | 1,500,000 | $26,580,000 | 0.60% |